跳转至内容
Merck

1029501

USP

苯磺酸氨氯地平(钙拮抗药)

United States Pharmacopeia (USP) Reference Standard

别名:

苯磺酸氨氯地平, 2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H25ClN2O5 · C6H5SO3H
分子量:
567.05
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

amlodipine

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC

InChI

1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)

InChI 密鑰

ZPBWCRDSRKPIDG-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

本产品按照现行药典要求提供和指定。所有为支持本产品而提供的信息,包括 SDS 和任何产品信息小册子,均由药典颁发机构制定和发布。如需进一步的信息和支持,请访问现行药典网站。如需进一步信息和支持,请访问现行药典网站。

應用

Amlodipine besylate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Amlodipine and Atorvastatin Tablets
  • Amlodipine and Benazepril Hydrochloride Capsules
  • Amlodipine and Olmesartan Medoxomil Tablets
  • Amlodipine and Valsartan Tablets
  • Amlodipine Besylate
  • Amlodipine Besylate Tablets
  • Amlodipine Compounded Oral Suspension

生化/生理作用

氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物,作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长,对雄性大鼠有抗生殖作用。

分析報告

这些产品仅供测试和分析使用。它们不适用于人类或动物的给药,不可用于诊断、治疗或治愈任何疾病。

其他說明

可能适用相应的销售限制。

相關產品

产品编号
说明
价格

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J M Krzesinski et al.
Revue medicale de Liege, 62(11), 688-694 (2008-01-26)
Hypertension is a common treatable risk factor for cardiovascular disease. Even when identified and treated, most patients with hypertension do not get to blood pressure goal and they often need at least two antihypertensive agents to achieve blood pressure control.
Roy Blank
Drugs of today (Barcelona, Spain : 1998), 42(3), 157-175 (2006-04-22)
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood pressure-lowering agent with pleiotropic effects, and atorvastatin calcium, a statin with lipid-lowering as well as pleiotropic
Rishi Puri et al.
Journal of the American College of Cardiology, 65(13), 1273-1282 (2015-04-04)
Statins can regress coronary atheroma and lower clinical events. Although pre-clinical studies suggest procalcific effects of statins in vitro, it remains unclear if statins can modulate coronary atheroma calcification in vivo. This study compared changes in coronary atheroma volume and calcium indices
Amlodipine besylate.
Gennady Ananchenko et al.
Profiles of drug substances, excipients, and related methodology, 37, 31-77 (2012-04-04)
C Venkata S Ram
Expert review of cardiovascular therapy, 9(1), 9-19 (2010-12-21)
Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality. Lowering blood pressure (BP) to recommended levels reduces the risk of hypertension-associated cardiovascular events. Despite current treatment options and recommendations, the BP of many

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门